Interfer Interferon Beta-1b: Pharmacology, Side Effects, Warnings, and Precautions

Overview:

Interferon beta-1b for MS (multiple sclerosis) is a widely employed medication that can reduce inflammation and progression of the disease. Interferon beta-1b gained authorization from the U.S. Food and Drug Administration (FDA) for treating the manifestations associated with multiple sclerosis on July 23, 1993. It is being licensed and marketed under various brand names with similar generic formulations. Besides interferon beta-1b, several other drug forms are used to treat multiple sclerosis. Concerned doctors analyze each patient and figure out the best choice of medicine for that particular individual by taking into account all the possible influential factors.

Drug Group:

Interferon beta-1b falls under the immunomodulatory class of drugs. Immunomodulators, as the name suggests, bring their action by altering the immune response. The actions can be either through up-regulation or down-regulation of the immune functions. It is employed to guide the immune response to a favorable route by either enhancing or inhibiting the immune reactions.

Available Doses and Dosage Forms:

Interferon beta-1b is marketed as a powder and solution, which can be delivered directly into the fatty layer underneath the skin via injection. Each injection formulation is designed to contain approximately 0.3 milligrams (mg) of powder, which must be mixed with a specific quality of liquid to obtain an injection solution with an accurate concentration of Interferon beta-1b.

For Patients:

How Does Interferon Beta 1B Work?

Interferon beta-1b helps calm the body's immune system when it becomes overly active. It prevents the immune cells from damaging the myelin, the protective covering of the brain and nerves. It can also fight some viruses. The medicine works by altering how immune cells receive their signals.

What Is the Dosage of Interferon Beta 1B?

The recommended starting dose is 0.0625 milligrams (mg). Interferon beta-1b is not recommended for daily administration; instead, it should be administered once every other day. The dose is gradually and steadily titrated biweekly over six-week periods until the preferred dose of 0.25 mg is reached.

How Effective Is Interferon Beta 1B?

Interferon beta-1b for the treatment of multiple sclerosis is highly efficacious in reducing both the intensity and frequency of disease exacerbations. Several clinical studies and trials have demonstrated the efficacy of Interferon beta-1b in treating multiple sclerosis. Several other studies have shown that effectiveness is influenced by patient factors, including their health status and the presence of comorbid conditions. The Interferon extended maximum benefits for multiple sclerosis type with marked relapses, where the treated person projected a dramatic decline in relapse rate.

What Are the Things to Inform the Doctor Before Taking the Drug?

Proper communication with the concerned medical professional is essential before commencing therapy with Interferon beta-1b. The complete patient's health status is crucial for the success of treatment, as it guides doctors in planning treatment and selecting the appropriate drugs.

• Allergy: Doctors must be informed about the patient's prior hypersensitivity or hyperreactivity to Interferon beta-1b or other related medications. Additionally, the entire ingredient list should be reviewed for potential allergen components, and if any are identified, they should be brought to the doctor's attention. The subsequent delivery of an allergen can trigger severe and alarming reactions in the body.

• Medical History: Detailed medical history encompassing all the information on the individual's health, like past illnesses, current health status, underlying ailments, past surgeries, and undergoing therapies. Certain disease conditions may worsen with Interferon beta-1b therapy; therefore, it is crucial to inform doctors of these conditions beforehand so that necessary adjustments in the drug choice can be made.

• Drug History: In addition to medical history, doctors need to be aware of all the medications a person takes, including herbal and dietary supplements. Some medications may interact with Interferon beta-1b. Knowing this helps the doctor choose the right medication and the correct dosage.

• Pregnancy and Lactation: The doctor should be informed of the patient's pregnancy and lactation status before commencing Interferon beta-1b. Pregnant women are not supposed to take all kinds of medicine, as they can potentially harm the baby in the womb. Similarly, lactating women may deliver the medicine into the child’s body through breast milk. Hence, the doctor needs to be updated on this.

What Should One Watch for While Using This Medication?

Things to watch for while using this medication are:

• Undergoing regular checkups to monitor the progress of the condition. Inform the doctor if the symptoms are not improving or if they are worsening.

• Undergoing regular blood tests to monitor for the side effects of interferon beta-1b.

• Other medications may be prescribed to reduce the risks; therefore, follow your doctor’s instructions carefully.

• Sometimes, this medication can cause thrombotic thrombocytopenic purpura (TTP), a rare blood disorder that is life-threatening, where blood clots can form throughout the body and require immediate help.

Look for the symptoms of this condition, such as:

• • Purple spots.

  • Flu-like symptoms.

  • Yellowing of the skin.

  • Headache.

  • Confusion.

  • Chest pain.

  • Fever.

  • Swelling in the legs.

  • Trouble speaking.

  • Trouble breathing.

  • Severe stomach pain.

  • Vision changes.

  • Difficulty urinating.

• Additionally, one should look for injection sites and allergic reactions and get medical help if necessary.

How Is Interferon Beta 1B Administered?

Interferon beta-1b is approved for delivery underneath the skin (subcutaneous) via shots. Trained medical professionals often perform it. However, caregivers or patients can administer the shot only if they are trained for that. The interferon beta-1b injection formulation is available in both powder and liquid forms, which must be reconstituted.

The Interferon beta-1b powder is made into a solution by adding a specific concentration of sodium chloride, which is available along with the powder in prefilled syringes. 1.2 milliliters of sodium chloride are added to the vial containing the powder. The vial is then gently rotated to ensure the thorough dissolution of the powder particles.

Each milliliter of the injection solution contains 0.25 milligrams of the drug molecules. The shelf life of the reconstituted injection formulation is three hours, provided it is stored at a temperature of 2 °C to 8°C (35°F to 46°F). The medicine can be injected subcutaneously with the help of a syringe loaded with the prescribed dosage of the reconstituted solution. The injection site needs to be changed alternately to check for trauma to a specific point.

What Are the Side Effects of Interferon Beta 1B?

Like other medications, Interferon beta-1b also causes specific adverse reactions following administration. Some of the routinely reported side effects concerning Interferon beta-1b include the following:

• Abnormal vaginal bleeding, headache, muscle stiffness, generalized weakness, and muscle soreness.

• Altered sexual drive, particularly in males.

• Injection site reactions may include tenderness, redness, puffiness, and rarely, bleeding.

• Impaired coordination (troubled walking and body movements).

Apart from the side effects mentioned above, there are specific alarming side effects associated with Interferon beta-1b that necessitate immediate medical attention.

Some of the grave reactions include the following:

• Yellow eyes or skin (jaundice).

• Pigmented urine and bloody stool.

• Not being able to sleep.

• Stomach pain.

• Suicidal thoughts and mental instability.

• Seizure (abnormal brain activity).

• Altered heartbeat.

• Short breath.

• Itchy rashes.

• Troubled talking.

• Swollen face.

• Chest pain.

If the patient experiences severe side effects, they should see a doctor immediately, as these problems can be dire.

Dietary Considerations:

You don’t have to eat any special foods if you are taking Interferon beta-1b. However, your doctor may offer you some dietary advice, depending on your overall health.

Missed Dose:

The Interferon drug injections are to be taken on alternate days. However, at times, the person may miss a dose of the injection. In such cases, the shot can be delivered once the patient becomes aware of the missed dose. However, a 48-hour interval needs to be maintained between each subsequent dose. If the patient accidentally delivers the medicine consecutively, immediate medical care needs to be sought, as it can give rise to toxicity issues.

Overdose:

Overdosage can result in increased body temperature, skin redness, and trouble breathing. In the event of these issues, seek immediate medical care. The patient must be monitored until all vital parameters return to normal range.

Storage:

Interferon beta-1b is marketed as a powder and a solution vial, and each vial is designed for single-use. The ideal temperature range for storing Interferon beta-1b is 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). However, temperatures within the range of 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit) are also reported to be safe for the storage of interference. After reconstitution, the residual solution is not intended for subsequent usage. It can be stored only for another three hours under refrigeration. Freezing the solution can alter the chemical and physical structure of the medicine, which can affect its therapeutic properties; therefore, it is not recommended.

For Doctors:

Indication:

Multiple sclerosis (relapsing form).

Dose:

The approved initial dose of Interferon beta-1b is 0.0625 mg, which corresponds to 0.25 milliliters of the reconstituted solution. Gradual dose titration is achieved every two weeks until the desired dose of 0.25 mg is attained. The final dose is attained within six weeks following the initial dose. One milliliter of the reconstituted solution contributes 0.25 mg of the drug molecule. The dose should be given once every two days.

Dosing Considerations:

No specific dose is considered, but the doctor may adjust according to the patient's health. The dose is designed so that the inceptive dose bears 25 percent of the intended dose. The dose is inflated by 25 percent biweekly until the intended dose is attained.

What Are the Pharmacological Aspects of Interferon Beta 1B?

Mechanism of action: Interferon beta-1b is a specific type of Interferon that alters the body’s immune response. However, limited information is available concerning the mechanism by which Interferon beta-1b tackles multiple sclerosis. It suppresses the proinflammatory cytokines but, at the same time, enhances the anti-inflammatory expression. Furthermore, Interferon beta-1b alleviates inflammation, particularly in the central nervous system, thereby checking the immune-mediated nerve cell impairments. All these properties work together to deal with the progression and manifestation of multiple sclerosis.

Pharmacodynamics: Interferon beta-1b alters the immunological response in distinct ways. The functions of T cells and B cells are modified under interference therapy. The activities of antigen-presenting cells and suppressor T cells will be silenced under the influence of Interferon beta-1b therapy. The trafficking of immune cells across the blood-brain barrier will be inhibited by Interferon beta-1b. It also depreciates the pro-inflammatory cytokine-mediated activities.

Pharmacokinetics: Following the injection of Interferon beta-1b, the drug molecules are immediately taken into the bloodstream. Following uptake, the drug molecules are distributed extensively throughout the body. Interferon beta-1b can extend its therapeutic effects on the central nervous system, as the blood-brain barrier does not restrict it.

Although interferon beta-1b is used as a medication, it is a protein-based medication. Therefore, the metabolism of interferon is quite different from that of other drugs. Interferon beta-1b is broken down into simpler amino acid molecules. The action of specific enzymes triggers this breakdown. The kidney plays a crucial role in eliminating interferon, and its half-life is estimated to be approximately five to six hours.

Toxicity: Interferon beta-1b therapy has demonstrated no carcinogenicity or mutagenicity in non-clinical studies. However, further research is needed to explore this topic in greater depth.

Clinical Studies: Clinical trials were conducted to assess the efficacy and safety of Interferon beta-1b in patients with MS. These were performed as placebo-controlled studies. The study subjects were chosen based on specific inclusion criteria. Patients with relapsing-remitting multiple sclerosis (RRMS) who satisfied all other inclusion criteria were selected as study subjects. The studies demonstrated dramatic depreciation in the relapse frequency associated with multiple sclerosis in patients on Interferon beta-1b therapy. Furthermore, certain patients even proved to be free of remissions following the therapy.

What Are the Contraindications of Interferon Beta 1B?

Interferon beta-1b therapy is not advisable in multiple sclerosis patients who have had prior allergic encounters with Interferon beta-1b or any of the components listed in the Interferon beta-1b injection formulation ingredient list. In addition, patients eliciting allergic responses to albumin-based medications are not supposed to undergo Interferon beta-1b therapy unless the probability of Interferon allergy is ruled out.

Warnings and Precautions:

• Cardiac Issues: Interferon beta-1b therapy is known to precipitate cardiac problems, particularly in patients with known heart problems. Patients who are already detected with cardiomyopathy or congestive heart failure require caution while undergoing Interferon beta-1b therapy. The exacerbation of heart problems is reported during the initial and dose alteration phase. However, there is no evidence to point out that Interferon beta-1b therapy can trigger cardiac issues in patients without any predisposition.

• Liver Damage: Interferon beta-1b can cause liver damage, and the presence of pre-existing liver disease can further increase this risk. Therefore, periodic assessment of the liver's functional status is important.

• Depressive Disorder: There are reports of depressive disorders in association with Interferon beta therapy. It is reported that Interferon beta-1b therapy enhances the probability of depression. In addition, the patients undergoing the therapy exhibited an enhanced suicidal tendency. Therefore, patients with known depressive disorders should refrain from Interferon-beta therapy. Similarly, the patients undergoing the therapy should be routinely assessed for clinical depression or suicidal thoughts. If depression is diagnosed, Interferon therapy needs to be withdrawn immediately.

• Leukopenia: Reports have been noted in patients undergoing Interferon beta-1b therapy, necessitating a reduction in the Interferon dose. Therefore, the blood profile needs to be assessed at regular intervals.

• Anaphylaxis: Rarely, Interferon beta may cause severe allergic reactions, including anaphylaxis. Bronchospasm, facial edema, and urticaria are the generally precipitated manifestations of anaphylaxis. In an anaphylactic reaction, immediate medical attention needs to be sought.

• Flu-Like Manifestations: Certain patients on Interferon therapy exhibit flu-like manifestations. In such cases, antipyretics can be employed to deal with the manifestations.

• Lupus Erythematosus: Interferon beta-1b is capable of triggering lupus erythematosus, where patients on Interferon elicit manifestations like rashes, joint issues, fever, shortness of breath, and many more. This form of lupus erythematosus, triggered by medication or drugs, is considered to be drug-induced lupus erythematosus.

• Thrombotic Microangiopathy: There are reports of thrombotic microangiopathy cases evoked by Interferon beta therapy. Therefore, patients should be cautioned about it. Immediately withdraw the drug if thrombotic microangiopathy is suspected.

• Injection Site Reactions: Certain skin reactions occur when responding to Interferon delivery at the injection site. Necrosis, soreness, erythema, and puffiness are routinely reported at injection points. Therefore, it is advisable to alternate the injection point to minimize the risk of injection site reactions.

• Pregnancy and Breastfeeding Warnings: During pregnancy or breastfeeding, this drug should be used only if the benefits outweigh the risks. Studies have shown that women taking Interferon beta 1b may have a preterm delivery, but there are no studies that determine the risk to infants. Even if the drug does pass into breast milk, the amount is extremely small because it is poorly absorbed orally, and it is not likely to reach the bloodstream of infants. Reports have shown that some mothers who took this drug while breastfeeding reported no adverse effects.

What Are the Drug Interactions of Interferon Beta 1B?

There is only limited information available regarding Interferon drug interactions. Interferon beta-1b tends to elicit an association with certain anticoagulants. Simultaneous delivery of Interferon beta-1b along with Ardeparin and Argatroban potentiates the anticoagulant property and augments bleeding risk.

Specific Considerations:

1. Interferon Beta-1B During Pregnancy: Expectant women are not supposed to take all sorts of medicines, as they carry the risk of fetal harm. Clinical studies fail to demonstrate an apparent association between Interferon beta-1b therapy and fetal harm or defects when delivered to a pregnant woman. However, considering the scope for fetal harm, Interferon therapy is indicated for a pregnant woman only if the risks override the anticipated maternal benefit.

2. Interferon Beta-1B During Lactation: There is no conclusive evidence about the discharge of Interferon beta-1b through breast milk. Therefore, it is routinely not advised for lactating women.

3. Interferon Beta-1B in the Pediatric Population: No studies have been conducted to assess the safety and efficacy aspects of Interferon Beta-1b in the pediatric population.

4. Interferon Beta-1B in the Geriatric Population: To obtain conclusive results, the number of seniors in clinical studies concerning Interferon Beta-1 b needed to be increased.